Feline leukaemia virus (FeLV) is a serious pathogen of cats. Persistent infections result in high rates of mortality particularly in younger cats. The virus is spread by close contact, between cats including cat fight wounds, or even licking and grooming. It is also transferred from an infected queen to her kittens while they are still in the womb. The time between infection with the virus and the appearance of signs of the disease may be very long – up to several years in some cases. Infected cats can appear healthy but still be a risk of infection to others.
Opalescent suspension for injection
Nobivac FeLV is an inactivated vaccine which contains 102 microgram per ml of purified p45 FeLV-envelope antigen, obtained by genetic recombination of a strain of E. coli. The antigenic suspension is adjuvanted with 1 ml of 3 % aluminium hydroxide gel and with 10 microgram purified extract of Quillaja saponaria.
Indications for use
For active immunisation of healthy cats to prevent persistent feline leukaemia virus viraemia and any associated clinical signs of feline leucosis. The onset of protection begins 2 weeks after immunisation. Following a first booster vaccination one year after the primary vaccination course, subsequent vaccinations can be performed at intervals of up to three years.
APET-plastic tray containing 10 or 50 single dose vials of vaccine
For full information please refer to the product data sheet. Further information is available on request.
Use Medicines Responsibly. For more information please refer to the Responsible Use sections of the NOAH website.
If you are not the prescribing veterinary surgeon, advice should be sought from the medicine prescriber.
Date of preparation: January 2018